Emily M. Leproust Sells 2,802 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 2,802 shares of the business's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $83,359.50. Following the completion of the transaction, the chief executive officer now owns 649,630 shares in the company, valued at $19,326,492.50. The trade was a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Twist Bioscience Stock Up 4.1%

Shares of NASDAQ:TWST traded up $1.15 during trading hours on Tuesday, reaching $29.41. The stock had a trading volume of 1,289,530 shares, compared to its average volume of 978,712. Twist Bioscience Co. has a 1 year low of $27.12 and a 1 year high of $60.90. The firm's 50 day moving average is $36.19 and its 200-day moving average is $42.60. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -8.70 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

TWST has been the topic of several recent analyst reports. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird decreased their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim restated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc grew its position in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of Twist Bioscience in the 4th quarter valued at $43,000. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Twist Bioscience in the 4th quarter valued at $58,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.